[(177)Lu-DOTA](0)-D-Phe(1)-Tyr(3)-Octreotide ((177)Lu-DOTATOC) For Peptide Receptor Radiotherapy in Patients with Advanced Neuroendocrine Tumours: A Phase-II Study

por Baum, Richard P., Kluge, Andreas W., Kulkarni, Harshad, Schorr-Neufing, Ulrike, Niepsch, Karin, Bitterlich, Norman, van Echteld, Cees J.A.
Publicado 2016

Results and adverse events of personalized peptide receptor radionuclide therapy with (90)Yttrium and (177)Lutetium in 1048 patients with neuroendocrine neoplasms

por Baum, Richard P., Kulkarni, Harshad R., Singh, Aviral, Kaemmerer, Daniel, Mueller, Dirk, Prasad, Vikas, Hommann, Merten, Robiller, Franz C., Niepsch, Karin, Franz, Holger, Jochems, Arthur, Lambin, Philippe, Hörsch, Dieter
Publicado 2018